JPRN-UMIN000006016
Not yet recruiting
未知
Phase 2 study of combination chemotherapy(VBL/PSL, MTX, 6MP) in patients with primary untreated adult langerhans cell histiocytosis - Combination chemotherapy in patients with primary untreated adult langerhans cell histiocytosis
Department of Hematology, International Medical Center, Saitama Medical University0 sites5 target enrollmentAugust 1, 2011
Conditionsadult langerhans cell histiocytosis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- adult langerhans cell histiocytosis
- Sponsor
- Department of Hematology, International Medical Center, Saitama Medical University
- Enrollment
- 5
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •A patient is uneligible if he (she) has (a) to (m). (a) SaO2 bellow 93% in room air. (b) Serum Cr level above 2\.0 mg/dL. (c) T.Bil level above 2\.0 mg/dL or GPT over 4 times of upper limit. (d) Uncontrolable DM using insurin. (e) Uncontrolable Hypertention. (f) History of myocardial infarction, congestive heart failure, unstable angina. (g) Resting ejection fraction bellow 50% by UCG. (h) Have an active cancer. (i) On or taking major tranquilizer, antidepressant, antimanic. (j) Uncontrollable active infection. (k) History of adverse reaction for the agents included in the protocol (l) Woman who is pregnant, possibly pregnant or breast feeding. (m) Inadequate for clinical trial entry by the attending physicians.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
Unknown
Phase 2
A phase II study of combination chemotherapy of oral tegafur/uracil, leucovorin and bevacizumab for patients not appropriate for intensive therapy with unresectable or recurrent colorectal cancerunresectable metastatic/recurrent colorectal cancerJPRN-UMIN000024330Dept of Surgical Oncology Osaka City University Graduate School of Medicine35
Completed
Phase 2
Phase II study of combination chemotherapy in treating pediatric patients with newly diagnosed intracranial germinomaJPRN-UMIN000002397Japanese Pediatric Brain Tumor Consortium50
Recruiting
Phase 2
Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancercolorectal cancerJPRN-UMIN000006793ippon Medical School Musashikosugi Hospital40
Completed
Phase 1
Phase 1/2 study of triple combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for chemotherapy-naïve stageIIIB/IV non- squamous non-small-cell lung cancer (TORG1424/OLCSG1402)Advanced stage IIIB/IV non-squamous non-small cell lung cancerJPRN-UMIN000014560Thoracic Oncology Research Group55